Malignant pleural effusion (MPE) affects more than 1 million people globally. There is a
dearth of evidence on the therapeutic approach to MPE, and not surprisingly a high degree …

Malignant pleural effusion is a frequent complication in many types of tumors, and its
presence indicates short expected survival. This review updates the current knowledge …

BACKGROUND: A malignant pleural effusion (MPE) is a late complication of malignancy
that affects respiratory function and quality of life. A strategy for palliation of the symptoms …

BACKGROUND: Malignant pleural effusion (MPE) has a limited life expectancy (3–
12months). We investigated the predictors of the early mortality (EM) within three months …

Background and objective Talc pleurodesis is commonly performed to manage refractory
pleural effusion or pneumothorax. It is considered as a safe procedure as long as a limited …

Background: Malignant pleural effusion, which is a common clinical problem in patients with
cancer, may be due to both primary thoracic tumours or to a metastatic spread in the chest …

Purpose Manifestations of malignant pleural effusions (MPEs) are alleviated by local
therapies as well as by systemic treatment. After 2009, when commercial use of talc was …

Objective Malignant pleural effusion is a severe and common complication in patients with
primary or metastatic malignancies of the pleura. Although talc pleurodesis is widely used …

Background Patients with malignant pleural effusion (MPE) are usually treated with an
indwelling pleural catheter (IPC) or pleurodesis. However, most do not achieve a satisfactory …

Background: Tunnelled pleural catheters used to treat malignant pleural effusions may
achieve pleurodesis. We aimed to identify factors associated with higher pleurodesis rates …